About: Cross Cancer Institute

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cross Cancer Institute Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Comprehensive cancer centre for northern Alberta

Attributes	Values
rdf:type	Item
owl:sameAs	Cross Cancer Institute
description	hôpital (fr) Krankenhaus (de) 병원 (ko) griya sakit (jv) rumah sakik (min) rumoh sakét (ace) مستشفى (ar) hospital de Canadá (ast) lamin pongusapan id Kanada (dtp) rumah sakit di Kanada (id) কানাডার একটি হাসপাতাল (bn) בית חולים בקנדה (he) ziekenhuis in Alberta, Canada (nl) Comprehensive cancer centre for northern Alberta (en)
rdfs:label	Cross Cancer Institute (en) معهد الصليب للسرطان (arz)
skos:prefLabel	Cross Cancer Institute (en) معهد الصليب للسرطان (arz)
name	Cross Cancer Institute (en) معهد الصليب للسرطان (arz)
Freebase ID	wds:Q5188247-4DA3A87D-D18A-4FDF-B52A-E09554FAD0EC
Freebase ID	/m/05s__3_
affiliation	wds:Q5188247-914852CF-D879-4F0E-943C-F0C6EABD9D2A
affiliation	University of Alberta
instance of	wds:Q5188247-9F9DB566-44E7-49F1-B772-EF773CB8D112
instance of	hospital
country	wds:q5188247-5AEA35D2-463D-4D7F-8B28-0AFB072F7A10
country	Malawi
Ringgold ID	wds:Q5188247-9EFC859B-BF42-4B05-A9E1-F6420A7CEABF
Ringgold ID	60294
inception	wds:Q5188247-B31EFD70-7910-4B02-9A3E-02D8CA4FF5A9
inception	1968-01-01 00:00:00Z (xsd:dateTime)
located in the adm...erritorial entity	wds:q5188247-F205F8B5-F590-4106-B32E-02CCC64DB2C3
ISNI	wds:Q5188247-C169BD06-9C45-4949-934E-DDF01BA3389B
VIAF ID	wds:Q5188247-BBE19AEF-5E2E-4502-8E87-122DF861B7A7
Library of Congress authority ID	wds:Q5188247-A4517E6B-464A-434C-A47C-142DEBD1CF9C
coordinate location	wds:q5188247-202B8FAE-1293-46D8-8A83-2A8E9AC786AE
Microsoft Academic ID	wds:Q5188247-8859A18B-404F-4A31-BF4A-E819DD210CEC
WorldCat Identities ID (superseded)	wds:Q5188247-D04899A4-4317-47CE-A69B-7364B7FE8E99
official website	wds:Q5188247-09AEFE52-E56C-47FF-9724-D5062A5B98F5
VIAF ID	http://viaf.org/viaf/130112383
Library of Congress authority ID	http://id.loc.gov/authorities/names/n85090088
Microsoft Academic ID	https://makg.org/entity/1307383912
located in the adm...erritorial entity	Edmonton
ISNI	0000000089276097
VIAF ID	130112383
Library of Congress authority ID	n85090088
coordinate location	POINT(-113.531 53.5178)
Microsoft Academic ID	1307383912
WorldCat Identities ID (superseded)	lccn-n85090088
official website	https://www.albertacancer.ca/cross-cancer-institute
is about of	Cross Cancer Institute Cross Cancer Institute https://www.wikidata.org/wiki/Special:EntityData/Q5188247 https://arz.wikipedia.org/wiki/%D9%85%D8%B9%D9%87%D8%AF_%D8%A7%D9%84%D8%B5%D9%84%D9%8A%D8%A8_%D9%84%D9%84%D8%B3%D8%B1%D8%B7%D8%A7%D9%86
is affiliation of	William Makis
is affiliation of	wds:Q118878096-9179b3f2-4643-bded-1183-914df4e365fd
is research site of	A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer A Study of LY3405105 in Participants With Advanced Cancer Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 1 and 2 Study of PX-866 and Cetuximab Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Topotecan in Treating Patients With Recurrent Brain Tumors PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Blood Test to Measure DNA Damage in Blood Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma Development of Magnetic Resonance (MR) Simulation for Treatment Planning A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy Comparative 2-D Tumor Analysis in Familial Gliomas Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases Vinorelbine in Treating Children With Recurrent or Refractory Cancers Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software